RET C634W

CI-VAR-00000353Explore in graph →NP_065681.1:p.Cys634TrpNM_020975.4:c.1902C>GClinVar 13918 CIViC 112 rs77709286

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Gastrointestinal Stromal Tumor1
RET C634W	Regorafenib Anhydrous	Predictive	D	Supports Sensitivity Response	—	submitted	EID3695 In an in vitro study, a TT cell line expressing RET C634W mutation demonstrated increased sensitivity to regorafenib treatment (IC50: 34nM vs. 560-3269nM) compared to HepG2, SW620, Colo-205 or A375 ce… (full text at CIViC) PMID 21170960 · Wilhelm et al., 2011 · Open in CIViC	civic
Thyroid Gland Medullary Carcinoma2
RET C634W	Axitinib	Predictive	D	Supports Resistance	—	submitted	EID3694 In an in vitro study, a MTC-TT cell line expressing RET C634W mutation (endogenous) demonstrated resistance to axitinib treatment (IC50: 1.56uM). Resistance was determined by assessing cell viability… (full text at CIViC)

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13918	Pathogenic	criteria provided, multiple submitters, no conflicts	2	Multiple endocrine neoplasia type 2A; Pheochromocytoma; Multiple endocrine neoplasia, type 2; Hereditary cancer-predisposing syndrome	germline	8	Dec 17, 2025	clinvar